Press Releases Merck KGaA

Stocks

MRK

DE0006599905

Pharmaceuticals

Market Closed - Xetra Other stock markets 23:35:28 16/07/2026 HKT			After hours 01:26:36
137.95 ^EUR	-1.53%		138.18	+0.16%

12:21am	Merck Opens BioReliance Testing Facility in Darmstadt Germany	CI
08:49pm	Merck KGaA Opens New Testing Facility at German HQ	MT

Press Releases

08:10pm	Merck : MilliporeSigma Announces BioReliance® Testing Facility Opening in Darmstadt, Germany	PU
07-14	Merck : European Commission Approves Erbitux® (cetuximab) in Combination with Encorafenib and FOLFOX for First-Line Treatment of Metastatic Colorectal Cancer with BRAF V600E Mutation	PU
07-08	Merck : Darmstadt, Germany, Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients with Active Skin Manifestations	PU
06-25	Merck KGaA: Merck Agrees to Acquire Bio-Techne Corporation	EQ
06-24	Merck : Darmstadt, Germany, Announces Healthcare Leadership Changes for Global Commercial Strategy and North America	PU
06-23	Merck : 2026 Future Insight Prize Goes to Spear’s Vasilis Ntziachristos	PU
06-08	Merck : MilliporeSigma Appoints New Heads of Discovery Solutions and Strategy & BD	PU
05-13	Merck : Q1 26 Financial Statement	PU
05-13	Merck : Q1 26 Press Release	PU
05-13	Merck : Q1 26 Summary	PU
05-13	Merck : Darmstadt, Germany, Delivers Solid Start to the Year and Upgrades Full-Year Guidance	PU
05-13	Merck : Strategic Update May 13, 2026	PU
05-05	Merck : Darmstadt, Germany, Opens €20 million Metrology and Inspection Site in France for Global Chip Industry	PU
04-30	Merck : Darmstadt, Germany, Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations	PU
04-25	Merck : (AGM 2026 Presence and Voting Results NA)	PU
04-25	Merck : (AGM 2026 Dividend Announcement NA)	PU
04-25	Merck : (AGM 2026 GOR Dividend EN NA)	PU
04-24	AGM: Beckmann to be appointed as CEO May 1	PU
03-25	Merck KGaA: Freifrau Helene Röder von Diersburg, buy	EQ
03-25	Merck KGaA: Belén Garijo Lopez, buy	EQ
03-14	Merck : Prospectus - C-032386	PU
03-12	Merck : (AGM 2026 Explanation Shareholder Rights EN NA)	PU
03-05	Merck : ESG Presentation	PU
03-05	Merck : Q4 25 Earnings Presentation	PU
03-05	Merck : Q4 25 Financial Statement	PU